中国肺癌杂志
中國肺癌雜誌
중국폐암잡지
CHINESE JOURNAL OF LUNG CANCER
2014年
4期
357-362
,共6页
EGFR-TKI%放疗%肺肿瘤
EGFR-TKI%放療%肺腫瘤
EGFR-TKI%방료%폐종류
EGFR-TKI%Radiotherapy%Lung neoplasms
肺癌是全球最常见的恶性肿瘤之一,严重威胁人类生命。近年来,以表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKIs)为首的靶向药物在肺癌治疗中取得巨大进展。因其具有高选择性和低毒性的优势,目前已成为IV期非小细胞肺癌(non-small cell lung cancer, NSCLC)EGFR突变患者的一线治疗方案。然而随着临床的广泛应用,继发耐药成为临床亟待解决的问题。近年来,基础研究证实, EGFR-TKI具有放射增敏性,理论上二者联合不但可以解决放疗后期肿瘤的放射抵抗以及EGFR-TKI继发耐药,还可以增加对肿瘤杀伤能力,同时副反应较同步放化疗小。因此,EGFR-TKI与放疗联合成为晚期NSCLC(IIIb期/IV期)极具探索的治疗模式。本文就EGFR-TKI与放疗联合治疗晚期NSCLC的基础与临床研究进展进行综述。
肺癌是全毬最常見的噁性腫瘤之一,嚴重威脅人類生命。近年來,以錶皮生長因子受體酪氨痠激酶抑製劑(epidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKIs)為首的靶嚮藥物在肺癌治療中取得巨大進展。因其具有高選擇性和低毒性的優勢,目前已成為IV期非小細胞肺癌(non-small cell lung cancer, NSCLC)EGFR突變患者的一線治療方案。然而隨著臨床的廣汎應用,繼髮耐藥成為臨床亟待解決的問題。近年來,基礎研究證實, EGFR-TKI具有放射增敏性,理論上二者聯閤不但可以解決放療後期腫瘤的放射牴抗以及EGFR-TKI繼髮耐藥,還可以增加對腫瘤殺傷能力,同時副反應較同步放化療小。因此,EGFR-TKI與放療聯閤成為晚期NSCLC(IIIb期/IV期)極具探索的治療模式。本文就EGFR-TKI與放療聯閤治療晚期NSCLC的基礎與臨床研究進展進行綜述。
폐암시전구최상견적악성종류지일,엄중위협인류생명。근년래,이표피생장인자수체락안산격매억제제(epidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKIs)위수적파향약물재폐암치료중취득거대진전。인기구유고선택성화저독성적우세,목전이성위IV기비소세포폐암(non-small cell lung cancer, NSCLC)EGFR돌변환자적일선치료방안。연이수착림상적엄범응용,계발내약성위림상극대해결적문제。근년래,기출연구증실, EGFR-TKI구유방사증민성,이론상이자연합불단가이해결방료후기종류적방사저항이급EGFR-TKI계발내약,환가이증가대종류살상능력,동시부반응교동보방화료소。인차,EGFR-TKI여방료연합성위만기NSCLC(IIIb기/IV기)겁구탐색적치료모식。본문취EGFR-TKI여방료연합치료만기NSCLC적기출여림상연구진전진행종술。
Lung cancer is one of the most common malignant tumor in the world, severely threatening human life. Recently, targeted therapy such as the epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) made huge progress in treatment of lung cancer. EGFR-TKIs, with its high selectivity and low toxicity, is the ifrst choice for EGFR-mutated patients in stage IV non-small cell lung cancer (NSCLC). However, secondary drug resistance becomes a clinical problem to be urgently resolved. In recent years, a series of preclinical studies showed that EGFR-TKI can enhance the antitumor activ-ity of ionizing radiation. hTerefore, EGFR-TKI combined with radiation is extremely promising therapy pattern for advanced NSCLC. hTis review will discuss the research status in EGFR-TKI and radiotherapy for advanced NSCLC.